Prescription Drug List Products for Human

Total Page:16

File Type:pdf, Size:1020Kb

Prescription Drug List Products for Human Prescription Drug List (Does not include medicinal ingredients listed in the Controlled Drugs and Substances Act Schedules) Products for Human Use Drugs containing any of the following: Including Effective date Qualifier (but not limited to) (yyyy‐mm‐dd) 2,4‐Dinitrophenol or its salts or derivatives 2013‐12‐19 4‐Amino‐pteroyl aspartic acid or its salts 2013‐12‐19 4‐Aminosalicylic Acid or its salts 2013‐12‐19 4‐Hydroxycoumarin or its derivatives Acenocoumarol when sold or recommended as anticoagulants 2013‐12‐19 5‐Aminosalicylic acid Mesalazine 2013‐12‐19 Abacavir or its salts 2013‐12‐19 Abatacept 2013‐12‐19 Abciximab 2013‐12‐19 Abiraterone or its derivatives Abiraterone acetate 2013‐12‐20 Acamprosate or its salts 2013‐12‐19 Acarbose or its derivatives 2013‐12‐19 Acebutolol or its salts 2013‐12‐19 Acepromazine or its salts 2013‐12‐19 Acetaminophen when recommended for administration by intravenous 2013‐12‐20 injection Acetanilide 2013‐12‐19 Acetazolamide 2013‐12‐19 Acetohexamide 2013‐12‐19 Acetylcarbromal 2013‐12‐19 Acetylcholine Chloride 2013‐12‐19 Acitretin or its salts or derivatives 2013‐12‐19 Aclidinium or its salts 2013‐12‐20 Aconiazide or its salts 2013‐12‐19 Acyclovir or its salts 2013‐12‐19 Adalimumab 2013‐12‐19 Adapalene or its salts or derivatives 2013‐12‐19 Adefovir or its salts or derivatives Adefovir dipivoxil 2013‐12‐19 Adenosine or its salts when sold or recommended for administration by 2013‐12‐19 intravenous injection Page 1 2017/09/15 Adrenocortical hormones or their salts or Betamethasone valerate, except: 2016‐08‐26 derivatives betamethasone sodium, a.hydrocortisone or hydrocortisone acetate, when sold as betamethasone phosphate, a single medicinal ingredient in a concentration that betamethasone dipropionate, budesonide, provides 1.0% or less hydrocortisone in preparations for ciclesonide, topical use on the skin; or, clobetasone, b.hydrocortisone or hydrocortisone acetate, when sold in cortisone, combination with any other nonprescription medicinal dexamethasone sodium, ingredient that provides 1.0% or less hydrocortisone in dexamethasone phosphate, dexamethasone acetate, preparations for topical use on the skin; or, difluprednate, c.clobetasone butyrate when sold in a concentration of fludrocortisone acetate, 0.05% in cream preparations for topical use on the skin; flunisolide, or, fluticasone propionate, d. triamcinolone acetonide in a nasal spray that delivers fluticasone furoate, hydrocortisone acetate, 55 microgram/spray for those 12 years of age and older; hydrocortisone aceponate, or, hydrocortisone sodium, e. Mometasone furoate for the treatment of allergic methylprednisolone acetate, rhinitis in a nasal spray that delivers 50 microgram/spray methylprednisolone, for those 12 years of age and older. methylprednisolone succinate, methylprednisolone sodium, f. Fluticasone propionate for the treatment of allergic mometasone furoate, rhinitis in a nasal spray that delivers 50 microgram/spray prednisolone acetate, for those 18 years of age and older. prednisolone sodium, prednisolone phosphate, prednisone, triamcinolone acetonide, triamcinolone hexacetonide Afatinib or its salts 2013‐12‐20 Aflibercept 2013‐12‐20 Afoxolaner 2014‐08‐21 Agalsidase Alfa, 2013‐12‐19 beta Albiglutide 2015‐08‐12 Aldesleukin 2013‐12‐19 Alectinib or its salts 2016‐11‐10 Alefacept 2013‐12‐19 Alemtuzumab 2013‐12‐19 Alendronic acid or its salts 2013‐12‐19 Alfacalcidol 2013‐12‐19 Alfuzosin or its salts 2013‐12‐19 Page 2 2017/09/15 Alglucosidase alfa 2013‐12‐19 Alirocumab 2016‐08‐09 Aliskiren or its salts 2013‐12‐19 Alitretinoin or its salts or derivatives 2013‐12‐20 Alkyl nitrites 2013‐12‐19 Allopurinol 2013‐12‐19 Allylisopropylacetylurea 2013‐12‐19 Almotriptan or its salts 2013‐12‐19 Alogliptin or its salts or derivatives 2013‐12‐20 Alpha‐chloralose 2013‐12‐19 Alphadolone or its salts 2013‐12‐19 Alpha‐hydroxy acids Citric acid, when sold in topical formulations containing alpha 2014‐12‐25 glycolic acid, hydroxy acids alone or in combination at concentrations lactic acid, greater than 30% and/or with a pH lower than 3.0, except malic acid, when sold to be applied to warts, corns or calluses. mandelic acid, ammonium glycolate, glycolic acid + ammonium glycolate, alpha‐hydroxyethanoic acid + ammonium alpha‐hydroxyethanoate, alpha‐hydroxyoctanoic acid, alpha‐hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, triple fruit acid, tri‐alpha hydroxy fruit acids, alpha hydroxy and botanical complex, l‐alpha hydroxy acid, glycomer in cross‐linked fatty acids alpha nutrium Alphaxalone Alfaxalone, 2013‐12‐19 alphaxolone Alteplase or its salts or derivatives Tenecteplase 2013‐12‐19 Altrenogest 2013‐12‐19 Altretamine 2013‐12‐19 Amantadine or its salts 2013‐12‐19 Ambenonium Chloride 2013‐12‐19 Page 3 2017/09/15 Ambrisentan 2013‐12‐19 Amifostine or its salts 2013‐12‐19 Amikacin or its salts or derivatives Amikacin sulfate 2013‐12‐19 Amiloride or its salts 2013‐12‐19 Aminocaproic acid 2013‐12‐19 Aminoglutethimide 2013‐12‐19 Aminolevulinic acid or its salts or 2013‐12‐19 derivatives Aminophylline 2013‐12‐19 Aminopterin or its salts or derivatives 2013‐12‐19 Aminopyrine or its derivatives 2013‐12‐19 Amiodarone or its salts or derivatives Dronedarone 2013‐12‐19 Amitraz 2013‐12‐19 Amitriptyline or its salts 2013‐12‐19 Amlexanox or its salts or derivatives 2013‐12‐19 Amlodipine or its salts 2013‐12‐19 Ammonium bromide 2013‐12‐19 Amoxapine 2013‐12‐19 Amphotericin B or its salts or derivatives 2013‐12‐19 Amprenavir or its salts or derivatives Fosamprenavir 2013‐12‐19 Amprolium or its salts 2013‐12‐19 Amrinone or its salts 2013‐12‐19 Amsacrine or its salts 2013‐12‐19 Anagrelide or its salts 2013‐12‐19 Anakinra or its salts or derivatives 2013‐12‐19 Anastrozole 2013‐12‐19 Ancestim 2013‐12‐19 Anidulafungin 2013‐12‐19 Antipyrine except preparations for topical use 2013‐12‐19 Anti‐thymocyte globulin 2013‐12‐19 Apixaban or its derivatives 2013‐12‐20 Apomorphine or its salts 2017‐02‐10 Apraclonidine or its salts 2013‐12‐19 Apramycin or its salts 2013‐12‐19 Apremilast 2014‐12‐04 Aprepitant or its derivatives Fosaprepitant 2013‐12‐19 Aprotinin 2013‐12‐19 Argatroban or its salts or derivatives 2013‐12‐19 Page 4 2017/09/15 Aripiprazole or its salts 2013‐12‐20 Arsenic trioxide 2013‐12‐19 Asenapine or its salts or derivatives Asenapine maleate 2013‐12‐20 Asfotase alfa 2015‐10‐16 Asparaginase when sold for administration by injection 2013‐12‐19 Astemizole or its salts 2013‐12‐19 Asunaprevir 2016‐08‐26 Atazanavir or its salts 2013‐12‐19 Atenolol or its salts 2013‐12‐19 Atezolizumab 2017‐05‐16 Atipamezole or its salts 2013‐12‐19 Atomoxetine or its salts 2013‐12‐19 Atorvastatin or its salts 2013‐12‐19 Atovaquone 2013‐12‐19 Atracurium besilate 2013‐12‐19 Atropine or its salts Atropine sulphate in ophthalmic or parenteral preparations 2013‐12‐19 Avermectin or its derivatives Ivermectin, 2013‐12‐19 selamectin, doramectin Avilamycin or its salts or derivatives 2014‐03‐12 Axitinib or its salts or derivatives 2013‐12‐20 Azacitidine or its salts or derivatives 2013‐12‐20 Azacyclonol or its salts 2013‐12‐19 Azaribine 2013‐12‐19 Azathioprine or its salts 2013‐12‐19 Azatidine or its salts or derivatives Azatadine 2013‐12‐19 Azelaic acid 2013‐12‐19 Azelastine or its salts 2014‐12‐05 Azilsartan medoxomil or its salts or 2013‐12‐20 derivatives Azithromycin or its salts or derivatives 2013‐12‐19 Aztreonam or its salts 2013‐12‐19 Baclofen or its salts 2013‐12‐19 Bambuterol or its salts 2013‐12‐19 Basiliximab 2013‐12‐19 Bazedoxifene or its salts 2014‐12‐04 Becaplermin 2013‐12‐19 Page 5 2017/09/15 Belimumab 2013‐12‐20 Bemegride 2013‐12‐19 Benactyzine or its salts 2013‐12‐19 Benazepril or its salts or derivatives Benazepril hydrochloride 2013‐12‐19 Bendamustine or its salts or derivatives Bendamustine hydrochloride 2013‐12‐20 Bendazac or its salts 2013‐12‐19 Benoxaprofen or its salts 2013‐12‐19 Benserazide or its salts 2013‐12‐19 Benzoyl peroxide in concentrations greater than 5% or when sold in 2013‐12‐19 combination with another medicinal ingredient Benztropine or its salts Benzatropine 2013‐12‐19 Benzydamine or its salts 2013‐12‐19 Bepotastine or its salts or derivatives 2016‐11‐10 Beractant 2013‐12‐19 Besifloxacin or its salts 2013‐12‐20 Betahistine or its salts 2013‐12‐19 Betaine or its salts when sold or recommended for the treatment of 2013‐12‐19 homocystinuria Betaxolol or its salts 2013‐12‐19 Bethanechol chloride 2013‐12‐19 Bethanidine or its salts 2013‐12‐19 Bevacizumab 2013‐12‐19 Bezafibrate or its salts or derivatives 2013‐12‐19 Bicalutamide 2013‐12‐19 Bilastine or its salts or derivatives 2016‐08‐26 Biperiden or its salts 2013‐12‐19 Bishydroxycoumarin or its salts or 2013‐12‐19 derivatives Bisoprolol or its salts 2013‐12‐19 Bitolterol or its salts 2013‐12‐19 Bivalirudin 2013‐12‐19 Bleomycin 2013‐12‐19 Blinatumomab 2016‐08‐09 Boceprevir or its derivatives 2013‐12‐20 Bortezomib 2013‐12‐19 Bosentan or its salts or derivatives 2013‐12‐19 Bosutinib or its salts Bosutinib methanoate 2014‐08‐21 Page 6 2017/09/15 Botulinum toxin Onabotulinumtoxin A, 2013‐12‐19 incobotulinumtoxin A, abobotulinumtoxin A, rimabotulinumtoxin B Brentuximab Vedotin 2013‐12‐20 Bretylium tosylate 2013‐12‐19 Brexpiprazole or its salts 2017‐04‐21 Brimonidine or its salts 2013‐12‐19 Brivaracetam or its derivatives 2016‐08‐09 Bromal 2013‐12‐19 Bromal hydrate 2013‐12‐19 Brometone 2013‐12‐19 Bromfenac or its salts 2015‐05‐28 Bromisoval 2013‐12‐19 Bromocriptine or its salts 2013‐12‐19 Bromoform 2013‐12‐19 Bumetanide or its salts or derivatives 2013‐12‐19 Bupropion or its salts 2013‐12‐19 Buserelin
Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Ontario Drug Benefit Formulary Edition 43
    Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Drug Programs Policy and Strategy Branch Ontario Public Drug Programs Ministry of Health and Long-Term Care Effective February 28, 2018 Visit Formulary Downloads: Edition 43 Table of Contents Part I Introduction ....................................................................................................... I.1 Part II Preamble .......................................................................................................... II.1 Part III-A Benefits List ........................................................................................... III-A.1 Part III-B Off-Formulary Interchangeable Drugs (OFI) ........................................ III-B.1 Part IV Section Currently Not In Use ......................................................................... IV Part V Index of Pharmacologic-Therapeutic Classification .................................... V.1 Part VI-A Facilitated Access - HIV/AIDS .............................................................. VI-A.1 Part VI-B Facilitated Access - Palliative Care ..................................................... VI-B.1 Part VI-C Temporary Facilitated Access - Rheumatology ................................. VI-C.1 Part VII Trillium Drug Program ................................................................................ VII.1 Part VIII Exceptional Access Program (EAP) ........................................................ VIII.1 Part IX-A Nutrition Products ................................................................................
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Information for the User ZYTIGA 500 Mg Film-Coated Tablets Abiraterone
    Package leaflet: Information for the user ZYTIGA 500 mg film-coated tablets abiraterone acetate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What ZYTIGA is and what it is used for 2. What you need to know before you take ZYTIGA 3. How to take ZYTIGA 4. Possible side effects 5. How to store ZYTIGA 6. Contents of the pack and other information 1. What ZYTIGA is and what it is used for ZYTIGA contains a medicine called abiraterone acetate. It is used to treat prostate cancer in adult men that has spread to other parts of the body. ZYTIGA stops your body from making testosterone; this can slow the growth of prostate cancer. When ZYTIGA is prescribed for the early stage of disease where it is still responding to hormone therapy, it is used with a treatment that lowers testosterone (androgen deprivation therapy ). When you take this medicine your doctor will also prescribe another medicine called prednisone or prednisolone. This is to lower your chances of getting high blood pressure, having too much water in your body (fluid retention), or having reduced levels of a chemical known as potassium in your blood.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Abiraterone Acetate for Chemotherapy-Naive
    Fan et al. BMC Urology (2018) 18:110 https://doi.org/10.1186/s12894-018-0416-6 RESEARCHARTICLE Open Access Abiraterone acetate for chemotherapy- naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors Liancheng Fan†, Baijun Dong†, Chenfei Chi†, Yanqing Wang†, Yiming Gong†, Jianjun Sha, Jiahua Pan, Xun Shangguan, Yiran Huang, Lixin Zhou* and Wei Xue* Abstract Background: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. Methods: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate- specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. Results: The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23. 3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively.
    [Show full text]
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares
    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]